[ad_1] School: School of Health and Life Sciences Contract: Full time/Fixed term (3 years) This is a full time/fixed term opportu
[ad_1]
School: School of Health and Life Sciences
Contract: Full time/Fixed term (3 years)
This is a full time/fixed term opportunity from 1 January 2024 – 31 December 2026
Project Outline:
A Medical Research Council-funded 3-year Postdoctoral Research Scientist position is offered to support p53 immuno-oncology research directed by Dr Timothy Humpton and Dr Jennifer Crowe. The project will be based at Glasgow Caledonian University (GCU) but will include a significant research component based at the CRUK Beatson Institute (also in Glasgow). In addition, the advertised position will provide a unique leadership role helping to direct an ambitious in vivo-led project with important translational potential. The position is offered as a 3-year fixed-term contract with starting salary from £36,333 pa.
Liver cancer is a common and lethal disease. As a result of the obesity epidemic, diet-induced liver disease (non-alcoholic steatohepatitis/NASH) represents an increasingly common cause of liver cancer. Worryingly, NASH-derived liver cancer can be especially resistant to therapy and is especially common in obese patients that also have type 2 diabetes mellitus. In NASH, an undue persistence of neutrophils has been shown to promote the development of treatment-resistant liver cancer in humans. Our preliminary findings suggest that the tumour suppressor p53 protects against the development of diet-induced NASH—and does so, at least in part, via neutrophil suppression.
With the proposed project, the appointed postdoc will investigate p53-mediated non-cell autonomous suppression of neutrophils in NASH-T2DM. To do so, they will utilise a suite of advanced technologies, including in vivo modelling, non-invasive imaging, confocal microscopy, flow cytometry, transcriptomics, and in vitro co-culture using patient-derived samples. With these tools, the appointed postdoc will help to characterise the relationship between p53 and neutrophil activity throughout diet-induced liver disease, determine the mechanisms that underpin this interaction, and examine the efficacy of proactively targeting neutrophils to prevent NASH.
Relevant recent publications from the group include:
Humpton et al. Science Signaling (2022). DOI: 10.1126/scisignal.abd9099.
Humpton et al. Cell Death & Differentiation (2021). DOI:10.1038/s41418-021-00871-3.
Humpton et al. Genes Dev. (2021). DOI: 10.1101/gad.341875.120.
Candidate:
The successful candidate will have a PhD in a relevant field, strong working knowledge of cancer biology, immunology, metabolic syndrome, or molecular mechanisms of disease and be a passionate and motivated scientist. The position will provide a unique leadership role helping to direct an ambitious in vivo-led project. As such, previous experience working with the key advanced technologies of the project, and especially with in vivo models of disease, advanced imaging techniques, flow cytometry, histopathology, bioinformatics, and/or metabolomics would be advantageous. However, extensive training will be provided.
You can apply for this role through the Glasgow Caledonian University vacancies page https://www.gcu.ac.uk/jobs/jobs
[ad_2]
Source link
COMMENTS